These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Pre-core mutants of hepatitis B virus in patients receiving immunosuppressive treatment after orthotopic liver transplantation. Protzer U; Goergen B; Hopf U; Neuhaus P; König V; Meyer zum Büschenfelde KH; Gerken G J Med Virol; 1996 Oct; 50(2):135-44. PubMed ID: 8915879 [TBL] [Abstract][Full Text] [Related]
43. Anti-hepatitis B virus activities of α-DDB-FNC, a novel nucleoside-biphenyldicarboxylate compound in cells and ducks, and its anti-immunological liver injury effect in mice. Yang Q; Zhao X; Zang L; Fang X; Zhao J; Yang X; Wang Q; Zheng L; Chang J Antiviral Res; 2012 Dec; 96(3):333-9. PubMed ID: 23098744 [TBL] [Abstract][Full Text] [Related]
44. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Moses SE; Lim Z; Zuckerman MA Expert Rev Anti Infect Ther; 2011 Oct; 9(10):891-9. PubMed ID: 21973301 [TBL] [Abstract][Full Text] [Related]
45. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218 [TBL] [Abstract][Full Text] [Related]
46. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. Vietheer PT; Netter HJ; Sozzi T; Bartholomeusz A J Virol; 2005 May; 79(10):6570-3. PubMed ID: 15858045 [TBL] [Abstract][Full Text] [Related]
47. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. Coppola N; Tonziello G; Colombatto P; Pisaturo M; Messina V; Moriconi F; Alessio L; Sagnelli C; Cavallone D; Brunetto M; Sagnelli E J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869 [TBL] [Abstract][Full Text] [Related]
48. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899 [TBL] [Abstract][Full Text] [Related]
49. Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Roche B; Roque-Afonso AM; Nevens F; Samuel D Transplantation; 2015 Jul; 99(7):1321-34. PubMed ID: 26038873 [TBL] [Abstract][Full Text] [Related]
50. Synthesis and anti-hepatitis B virus activity of C4 amide-substituted isosteviol derivatives. Huang TJ; Yang CL; Kuo YC; Chang YC; Yang LM; Chou BH; Lin SJ Bioorg Med Chem; 2015 Feb; 23(4):720-8. PubMed ID: 25600408 [TBL] [Abstract][Full Text] [Related]
51. Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. Billioud G; Pichoud C; Parent R; Zoulim F J Hepatol; 2012 Jun; 56(6):1269-75. PubMed ID: 22314422 [TBL] [Abstract][Full Text] [Related]
52. The difficulties of managing severe hepatitis B virus reactivation. Roche B; Samuel D Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146 [TBL] [Abstract][Full Text] [Related]
53. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241 [TBL] [Abstract][Full Text] [Related]
54. Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. Cento V; Van Hemert F; Neumann-Fraune M; Mirabelli C; Di Maio VC; Salpini R; Bertoli A; Micheli V; Gubertini G; Romano S; Visca M; De Sanctis GM; Berkhout B; Marino N; Mazzotta F; Cappiello G; Spanò A; Sarrecchia C; Ceccherini-Silberstein F; Andreoni M; Angelico M; Verheyen J; Perno CF; Svicher V J Infect; 2013 Oct; 67(4):303-12. PubMed ID: 23796863 [TBL] [Abstract][Full Text] [Related]
55. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Lai MW; Yeh CT Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921 [TBL] [Abstract][Full Text] [Related]
56. Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy. Lin CL; Chien RN; Hu CC; Lai MW; Yeh CT J Antimicrob Chemother; 2012 Jan; 67(1):39-48. PubMed ID: 22001270 [TBL] [Abstract][Full Text] [Related]
57. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790 [TBL] [Abstract][Full Text] [Related]
58. [The inhibitory effect of Chinese herb Phyllanthus on hepatitis B virus in vitro]. Liu Z; Fu X; Zhang N; Zhang G; Liu D Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):282-5. PubMed ID: 15617349 [TBL] [Abstract][Full Text] [Related]
60. [Low frequency of precore stop mutation in patients with dual infection of hepatitis B and C viruses]. Qiu W; Hou J; Lou K Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun; 12(2):133-5. PubMed ID: 12515190 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]